Antares Pharma Inc (NASDAQ:ATRS) shares were up 10.9% on Thursday . The stock traded as high as $2.78 and last traded at $2.75. Approximately 2,125,710 shares changed hands during trading, an increase of 64% from the average daily volume of 1,292,881 shares. The stock had previously closed at $2.48.
Several research analysts have weighed in on ATRS shares. BidaskClub raised shares of Antares Pharma from a “hold” rating to a “buy” rating in a report on Friday, December 22nd. HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Antares Pharma in a report on Thursday, February 15th. Finally, ValuEngine raised shares of Antares Pharma from a “sell” rating to a “hold” rating in a report on Friday. One analyst has rated the stock with a hold rating, four have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $3.94.
The firm has a market cap of $430.86, a price-to-earnings ratio of -25.36 and a beta of 0.23. The company has a debt-to-equity ratio of 0.69, a current ratio of 3.34 and a quick ratio of 2.89.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3254005/antares-pharma-atrs-trading-up-10-9.html.
Antares Pharma Company Profile
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.
Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.